Zevra reported third-quarter total net revenue of $37.8 million, up 45%, net income of $19.2 million and $270.9 million in cash, cash equivalents, and investments. MyPyFA generated $34 million in U.S. net sales; an SNDA is planned for the first quarter of 2027.
ZVRA · Zevra Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Zevra Therapeutics reported nine-month 2026 revenue of $113.6 million and net income of $65.9 million, including a $43.3 million gain from selling assets under the Commave Settlement Agreement. Cash, cash equivalents and investments totaled $270.9 million.
Zevra Therapeutics reported $37.8 million in Q3 2026 net revenue, up 45% from Q3 2025, including $34.0 million from MIPLYFFA. Net income was $19.2 million, and cash, cash equivalents and investments totaled $270.9 million as of September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. Q3 net revenue rose 45% to $37.8 million, including $34.0 million of MIPLYFFA revenue, and Zevra reported $19.2 million of net income, $270.9 million of cash, cash equivalents and investments, 197 cumulative enrollment forms, 69% payer coverage, and continued Phase 3 DiSCOVER enrollment. Operating and product costs increased, European approval remains unresolved, the pediatric expansion represents a relatively small patient population and is not expected to increase TAM prevalence, and MIPLYFFA carries stated serious safety and withdrawal risks.
- + Q3 total net revenue increased 45% to $37.8 million, including $34.0 million of MIPLYFFA net revenue. new
- + Zevra reported Q3 net income of $19.2 million, or $0.31 per basic and $0.26 per diluted share, versus a $0.5 million net loss a year earlier. new
- + Cash, cash equivalents and investments increased approximately $10.7 million from June 30, 2026 to $270.9 million at September 30, 2026. new
- + Management plans to file a pediatric MIPLYFFA sNDA in Q1 2027, while cited patent protection extends to 2041 and U.S. orphan drug exclusivity runs through 2031. new
- + The Phase 3 DiSCOVER trial enrolled six additional celiprolol patients in Q3 to reach 72, and management is pursuing a potential accelerated submission strategy with the FDA. new
- − European approval remains unresolved while arimoclomol's Marketing Authorization Application is undergoing reexamination. new
- − Management characterized the under-24-month label expansion as a relatively small patient population, estimated in the ballpark of 5%. new
- − MIPLYFFA's prescribing information identifies serious adverse reactions and withdrawal risks. new
- − The pediatric expansion is not expected to increase total addressable market prevalence. new
- − Cost of product revenue increased to $1.8 million in Q3 2026 from $1.2 million in Q3 2025, excluding intangible asset amortization. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| sales of MIPLYFFA | $34M | FY2026 Q3 | +51.8% |
|
|
|||
| Adjusted net income per diluted share non-GAAP | $0.25 | Q2 2026 | — |
| Adjusted quarterly net income non-GAAP | $15.2M | Q2 2026 | — |
| Confirmed events in the Phase 3 DiSCOVER trial | 3 | Q2 2026 | — |
| Fully diluted common shares | 69,298,105 | As of June 30, 2026 | — |
| Market access (covered lives) | 69% | Q2 2026 | — |
| MIPLYFFA prescription enrollment forms | 14 | Q2 2026 | — |
| Patients enrolled in the global Expanded Access Program | 132 | As of June 30, 2026 | — |
| Patients enrolled in the Phase 3 DiSCOVER trial of celiprolol | 66 | Q2 2026 | — |
| revenue related to the global EAP | $9M | three months ended June 30, 2026 filing | — |
| revenue under the AZSTARYS License Agreement | $0.3M | three months ended June 30, 2026 filing | — |
| sales of OLPRUVA | $0.2M | three months ended June 30, 2026 filing | — |
| Total MIPLYFFA prescription enrollment forms since product launch | 184 | Q2 2026 | — |
| Total shares of common stock outstanding | 59,341,906 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZVRA
this stock
Zevra Therapeutics, Inc.
|
$552.20M | +3.6% | +350.9% | 7.2 | 11.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 15
Zevra Therapeutics reported $37.8 million in Q3 2026 net revenue, up 45% from Q3 2025, including $34.0 million from MIPLYFFA. Net income was $19.2 million, and cash, cash equivalents and investments totaled $270.9 million as of September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZVRA | -21.7% | -10.4% | -19.9% | -9.7% | +3.6% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -17.8% | -4.9% | -16.5% | -6.4% | -3.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.